- Home
- ILAG vs IMRN Comparison
ILAG vs IMRN Comparison
Compare ILAG & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- IMRN
- Stock Information
- Founded
- ILAG 1981
- IMRN 1994
- Country
- ILAG Hong Kong
- IMRN Australia
- Employees
- ILAG N/A
- IMRN N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- IMRN Health Care
- Exchange
- ILAG Nasdaq
- IMRN Nasdaq
- Market Cap
- ILAG 15.9M
- IMRN 15.0M
- IPO Year
- ILAG 2022
- IMRN N/A
- Fundamental
- Price
- ILAG $0.87
- IMRN $1.91
- Analyst Decision
- ILAG
- IMRN Strong Buy
- Analyst Count
- ILAG 0
- IMRN 1
- Target Price
- ILAG N/A
- IMRN $5.00
- AVG Volume (30 Days)
- ILAG 44.2K
- IMRN 5.6K
- Earning Date
- ILAG 01-17-2025
- IMRN 02-26-2025
- Dividend Yield
- ILAG N/A
- IMRN N/A
- EPS Growth
- ILAG N/A
- IMRN N/A
- EPS
- ILAG N/A
- IMRN N/A
- Revenue
- ILAG $8,980,747.00
- IMRN $3,271,194.00
- Revenue This Year
- ILAG N/A
- IMRN N/A
- Revenue Next Year
- ILAG N/A
- IMRN N/A
- P/E Ratio
- ILAG N/A
- IMRN N/A
- Revenue Growth
- ILAG 33.03
- IMRN 171.67
- 52 Week Low
- ILAG $0.33
- IMRN $1.59
- 52 Week High
- ILAG $1.35
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- ILAG 42.10
- IMRN 47.53
- Support Level
- ILAG $0.83
- IMRN $1.70
- Resistance Level
- ILAG $0.98
- IMRN $2.09
- Average True Range (ATR)
- ILAG 0.07
- IMRN 0.13
- MACD
- ILAG 0.00
- IMRN -0.02
- Stochastic Oscillator
- ILAG 30.00
- IMRN 40.00
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.